BioMaxima

BioMaxima Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of BioMaxima (BMX.WA) as of Oct 17, 2026 is 2,224.76 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was -28.41 % — a change of -7,930.58% (higher).

Cash Conversion

2,224.76 %

YoY

-7,930.58%

Last updated:

Cash Conversion Rate (OCF/Net Income) of BioMaxima is 2025 2,224.76 % . Cash Conversion Rate (OCF/Net Income) of BioMaxima was 2024 -28.41 % . It decreases by -7,930.58% higher compared to the previous year.

The BioMaxima Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
-439.90 PLN
Jan 1, 2019
-36,485.87 PLN
Jan 1, 2020
49.98 PLN
Jan 1, 2021
-1.29 PLN
Jan 1, 2022
128.32 PLN
Jan 1, 2023
271.67 PLN
Jan 1, 2024
-28.41 PLN
Jan 1, 2025
2,224.76 PLN
The BioMaxima Cash Conversion history
YEARCash ConversionYoY
2,224.76 %-7,930.58%
-28.41 %-110.46%
271.67 %+111.72%
128.32 %-10,057.38%
-1.29 %-102.58%
49.98 %-100.14%
-36,485.87 %+8,194.11%
-439.90 %-292.68%
228.30 %+94.76%
117.22 %-25.43%
157.20 %+27.45%
123.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioMaxima Stock analysis

What does BioMaxima do? BioMaxima SA is a company based in Lublin, Poland, operating within the Health Care sector, specifically in the Health Care industry. The company went public via an IPO on June 8, 2010, and is listed under the ticker BMX.WA with ISIN PLBIOMX00015. BioMaxima SA specializes in biotechnology and laboratory diagnostics, manufacturing and distributing reagents and equipment for laboratory diagnosis. The company produces in vitro diagnostic reagents and offers a range of products including diagnostic reagents and analyzers for clinical biochemistry, rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers, and drugs of abuse, urine analysis systems, hematology analyzers and reagents, ion-selective analyzers and reagents, reagents and immunological analyzers for cardiac markers, glucometers, and analyzers for gasometric and critical blood parameters tests. BioMaxima SA supplies hospitals and laboratories across Poland, Lithuania, Latvia, Romania, and France. The company merged with its wholly owned subsidiary Cebo Sp z o o on March 20, 2014. The company's website is https://biomaxima.com/. BioMaxima is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioMaxima stock

Cash Conversion Rate (OCF/Net Income) of BioMaxima is 2,224.76 % in 2025.

Cash Conversion Rate (OCF/Net Income) of BioMaxima changed from -28.41 % to 2,224.76 %, representing a -7,930.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) BioMaxima since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s BioMaxima with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioMaxima

All Key Metrics — BioMaxima